Yoshikawa, T., Terashima, M., Mizusawa, J., Nunobe, S., Nishida, Y., Yamada, T., et al. (2019) Four Courses versus Eight Courses of Adjuvant S-1 for Patients with Stage II Gastric Cancer (JCOG1104 [OPAS-1]): An Open-Label, Phase 3, Non-Inferiority, Randomised Trial. The Lancet Gastroenterology and Hepatology, 4, 208-216.
https://doi.org/10.1016/S2468-1253(18)30383-2

has been cited by the following article:

• TITLE: Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

  AUTHORS: Junjian Liu, Tian Wei, Zhiping Xiang, Yinlu Ding

  KEYWORDS: Locally Advanced Gastric Cancer, Adjuvant Chemotherapy, Neoadjuvant Chemotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 30, 2023

  ABSTRACT: Gastric cancer is one of the most common malignant tumours worldwide, with a high degree of malignancy and a poor prognosis. While early gastric cancer can be cured by surgical treatment, locally advanced gastric cancer requires neoadjuvant therapy to shrink the tumour, suppress potential metastases, achieve down-staging, and provide patients with the opportunity for radical surgery to prolong their survival. This article reviews the current status and progress of neoadjuvant chemotherapy for locally advanced gastric cancer.